Cargando…
Moexipril and left ventricular hypertrophy
Angiotensin-converting enzyme (ACE) inhibitors today are the standard therapy of patients with myocardial infarction and heart failure due to their proven beneficial effects in left ventricular remodeling and left ventricular function. ACE inhibitors have also been demonstrated to lead to regression...
Autores principales: | Chrysant, George S, Nguyen, PK |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994034/ https://www.ncbi.nlm.nih.gov/pubmed/17583172 |
Ejemplares similares
-
Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers
por: Bacharova, Ljuba, et al.
Publicado: (2023) -
Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)
por: Cameron, Ryan T., et al.
Publicado: (2013) -
Left ventricular hypertrophy: is it really?
por: Mikolich, J Ronald, et al.
Publicado: (2013) -
Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options
por: Sayin, Begum Yetis, et al.
Publicado: (2022) -
Myocardial Energetics in Left Ventricular Hypertrophy
por: Jameel, Mohammad N, et al.
Publicado: (2009)